Breaking AI & Tech News Analyzed

For the first time, thousands of cancer patients from Black and minority ethnic backgrounds will benefit from an enhanced genetic test offered by the NHS. The new screening expands the panel of DPYD gene variants from four to five, directly addressing a long‑standing bias that left non‑white patients vulnerable to dangerous chemotherapy side‑effects. In England, patients slated for chemotherapy undergo a genetic check that can guide dose adjustments and mitigate adverse reactions such as mouth sores, hair loss, nausea, fatigue, and, in severe cases, death. Up to 40% of the 38,000 individuals receiving fluoropyrimidine‑based chemotherapy each year experience a harmful drug reaction. Previously, the test only targeted four DPYD variants common in people of European descent, meaning many Black patients received inaccurate “all‑clear” results. The addition of a fifth variant—more prevalent among African, Caribbean and other minority groups—means clinicians can now identify patients at risk who were previously missed. Since its rollout at Manchester University NHS Foundation Trust last September, three minority‑ethnic patients have had their initial chemotherapy doses adjusted, lowering their chance of a potentially fatal reaction. Dr Veline L’Esperance, senior clinical adviser at the NHS Race and Health Observatory, called the change “tangible results for patients who have historically been left behind.” She emphasized that the update shifts the discussion on ethnic health inequality from rhetoric to actionable care. Prof Habib Naqvi, chief executive of the NHS Race and Health Observatory, described the development as a “groundbreaking outcome” for chemotherapy safety, while noting that ethnic minorities remain under‑represented in genomic research and biobanks. He warned that broader inclusion is essential for the promised benefits of precision medicine to reach all communities. Prof Dame Sue Hill, chief scientific officer for NHS England, highlighted the significance of discovering the fifth variant: “Personalising chemotherapy based on genetics can save lives and reduce harmful side‑effects, especially for patients of African ancestry.” She added that the North West NHS Genomic Medicine Service has already demonstrated the practical impact of this approach. These steps come amid broader evidence that minority patients in the UK face longer diagnostic waits, more GP visits before a cancer diagnosis, and lower perceived support during treatment. The expanded DPYD test represents a concrete effort to close those gaps and ensure equitable, science‑driven care for all cancer patients.

World Aquatics, the governing body for swimming, diving, and water polo, has lifted restrictions on Russian and Belarusian athletes, allowing them to compete under their own flag and anthem for the first time since 2022. This decision has been met with outrage in Ukraine and joy in Russia, adding momentum to Russia's bid to participate in the 2028 Los Angeles Olympic Games. Ukrainian athletes have expressed their disappointment and anger over the decision. Vladyslav Heraskevych, a Ukrainian skeleton star, described the move as 'unacceptable and disgraceful', highlighting the ongoing conflict between Russia and Ukraine and its impact on Ukrainian athletes and sports facilities. The decision by World Aquatics follows a similar move by judo last year and comes as the International Olympic Committee (IOC) considers removing restrictions on Russian and Belarusian athletes for international events. The IOC recommended allowing Russians to compete under national flags in December, while the International Paralympic Committee has already permitted Russians to compete under their own flag and anthem. Russia has welcomed the decision, with Dmitry Mazepin, head of the Russian Aquatics Federation, stating that competing as a neutral athlete was 'an insult'. This development has significant implications for international sports and the participation of Russian athletes in future competitions.

More than 1,000 film and television professionals have signed an open letter opposing Paramount’s pending acquisition of Warner Bros Discovery, a deal valued at $111 billion. The signatories include high‑profile names such as Joaquin Phoenix, Ben Stiller, Mark Ruffalo, Yorgos Lanthimos, Kristen Stewart, Jane Fonda, and Emma Thompson.The letter, published on BlocktheMerger.com, warns that the merger would undermine the integrity, independence and diversity of the U.S. media sector, consolidating the number of major studios to just four and jeopardising a "vibrant future" for what it calls America’s "single most significant export" – its cultural content.Signatories argue that media consolidation already weakens competition, leading to fewer mid‑budget films, reduced independent distribution, higher production costs and fewer jobs across the ecosystem. They stress that competition is essential for both a healthy economy and a healthy democracy.Among the notable supporters are directors Denis Villeneuve, Boots Riley, Mimi Leder and Nicole Holofcener, as well as TV veterans David Chase, Noah Wyle, Ramy Youssef, Rob Delaney, Jason Bateman and Ted Danson. The letter also praises California Attorney General Rob Bonta and other state officials for scrutinising the deal.Paramount CEO David Ellison, who outbid Netflix for Warner Bros, claims the merger will boost creative output, pledging to release 30 theatrical titles annually and invest in both studios. Critics, however, remain skeptical, pointing to the Ellisons’ political ties and the risk of fewer politically‑engaged films.Recent accolades underscore the stakes: Warner Bros productions captured a record 11 Oscars in March, while Paramount films earned no nominations. The industry fears that the combined entity could further diminish quality and lead to significant job losses.Paramount has responded with a statement emphasizing that the transaction will “create a company that can greenlight more projects, back bold ideas, support talent across multiple stages of their careers, and bring stories to audiences at a truly global scale—while strengthening competition.” The letter’s authors remain unconvinced, urging regulators to block the merger to preserve competition, protect jobs, and safeguard the cultural export that defines American cinema.

World champion boxer Terence Crawford was found guilty of careless driving on Monday and ordered to pay a $75 fine stemming from a traffic stop last year that led to a gunpoint incident. The incident occurred on September 28, hours after Crawford's hometown of Omaha held a parade to celebrate his unanimous-decision victory over Canelo Álvarez in a super middleweight championship fight.Crawford was stopped by police after officers observed his vehicle driving recklessly. During the stop, Crawford's head of security informed an officer that he was carrying a legal firearm, and seconds later, another officer spotted a gun on the floorboard. With guns drawn, officers ordered everyone out of the vehicle. Crawford claimed he had leaned over to tell the officer that he also had a legal firearm, but the officer didn't hear him. Police confirmed that all occupants of the vehicle were legally permitted to carry firearms.The traffic stop led to an internal investigation by the Omaha police chief into the officers' actions, which was found to have been lawful. In addition to the $75 fine, Crawford was ordered to pay $49 in court costs. This incident comes after Crawford announced his retirement in December with a 42-0 record and 31 knockouts, making him the first male boxer to capture three unified division titles.

Conversations about mundane topics are often dreaded, but research suggests that people enjoy them more than they anticipate. A study involving 1,800 volunteers found that participants enjoyed chatting about dull subjects, such as the stock market or vegan diets, more than they expected. The findings indicate that by avoiding potentially dull exchanges, individuals may miss out on the mood boost and health benefits that come with connecting with others. Elizabeth Trinh, a PhD candidate in management and organisations at the University of Michigan, noted that people tend to underestimate how interesting and enjoyable conversations about boring topics can be. Trinh and her colleagues conducted a series of experiments to gauge how people responded to conversations on dull topics. Participants were asked to predict how much they would enjoy discussing topics they considered boring, and then engage in brief conversations about those topics. The results, published in the Journal of Personality and Social Psychology, showed that people consistently found the conversations more enjoyable than they expected. The surprise enjoyment arises because individuals base their expectations on static components, such as the topic and the other person, rather than dynamic components, like the conversation itself. Trinh suggests that people may benefit from lowering the bar for what makes a conversation worth having and reframing conversational goals. Instead of focusing on enjoyment, individuals could think about what they might learn from the conversation. Nicholas Epley, a professor of behavioural science at the University of Chicago, added that the fear of a boring conversation shouldn’t prevent people from starting one. “If a conversation is boring once you’re in it, you also have a surprising amount of power to make it better!”

Meta, the company behind Facebook and Instagram, is reportedly working on an AI version of its CEO, Mark Zuckerberg. This AI clone is being trained on Zuckerberg's mannerisms, tone, and public statements to allow employees to interact with a digital version of their boss.The rationale behind this project is to make Meta's 79,000 employees feel more connected to one of the most influential figures in Silicon Valley. The AI character will be developed using images and the voice of Zuckerberg, with the CEO reportedly taking part in the training process.This move is part of Meta's broader effort to integrate AI into its business operations. The company aims to use AI to lower costs and accelerate work pace. Zuckerberg has emphasized the importance of efficiency, stating that the goal is to 'get more done' by elevating individual contributors and flattening teams.The development of this AI character follows Meta's previous experiments with digital avatars. In 2022, Zuckerberg shared his own avatar in the metaverse, which received public criticism for its graphic quality. The company has since scaled back its metaverse vision, focusing on AI-generated 3D characters for everyday conversations.Meta's investment in AI is part of a larger strategy to remain competitive with tech rivals. The company is pouring billions of dollars into AI research to create 'superintelligence,' a system capable of performing any cognitive task far better than a human.

Sam Neill, the veteran actor celebrated for his memorable performances on screen, is set to answer readers' questions in an upcoming interview with The Guardian. Neill's iconic roles include his portrayal in Jurassic Park, where he famously removes his sunglasses and gazes at a towering Brachiosaurus, a scene that has become etched in cinematic history.Born in Northern Ireland and raised in New Zealand, Neill's diverse filmography showcases his versatility as an actor. He has appeared in a range of films, from period dramas like My Brilliant Career to thrillers such as Dead Calm, which is set to be released in 4K later this year. His recent projects include Godzilla x Kong: Supernova, alongside Kaitlyn Dever and Matthew Modine.Neill's career has been marked by his ability to take on idiosyncratic, director-led projects, often playing characters with a unique blend of gruffness and warmth. His performances in Sweet Country and Rams have been particularly noted for their depth and nuance.In addition to his film work, Neill has also made headlines for his memoir, Did I Ever Tell You This?, in which he openly discusses his experience with stage-three blood cancer and his journey towards remission. When asked about his mortality, Neill expressed a pragmatic view, stating, “I’m not afraid to die, but it would annoy me”.Readers are invited to post their questions for Sam Neill by 6pm BST, Thursday 16 April, and The Guardian will publish his answers in their reader interview series. This provides a unique opportunity for fans to engage with one of cinema's most beloved actors and gain insight into his life and career.

Recent CDC data reveal a dramatic 1,200% increase in kratom‑related poisonings across the United States over the last ten years, with the most pronounced surge recorded in 2025. Researchers link this rise to the growing presence of 7‑hydroxymitragynine (7‑OH), a synthetically produced compound that mimics kratom’s effects but carries opioid‑like risks. Walter Prozialeck, pharmacology professor at Midwestern University, said the trend was expected, noting that the synthetic alkaloid has entered the market through energy drinks and other products since 2024. Christopher McCurdy of the University of Florida warned that marketing 7‑OH as “enhanced kratom” blurs the line for consumers, turning poison‑control calls into a conflated metric for both natural and synthetic products. By contrast, natural kratom (Mitragyna speciosa)—a Southeast Asian plant used for centuries as a pain reliever—has demonstrated a relatively favorable safety profile in animal and human studies. A 2018 statement from then‑HHS Secretary Brett Giroir rejected the DEA’s push to schedule kratom as a Schedule I substance, citing insufficient evidence of harm. Despite the scientific distinction, several states have moved to implement or propose blanket bans on all kratom products, prompting concern from clinicians and patient advocates. A recent user survey indicated that about 50% of respondents rely on kratom for chronic pain, while roughly 40% use it during addiction recovery. Personal testimonies underscore the plant’s therapeutic role. Jeff Maslan, a 68‑year‑old Californian with severe osteoarthritis, credits kratom with easing opioid withdrawal after multiple surgeries. Similarly, “Steven,” a disabled California resident, describes how kratom eliminated unbearable oxycodone withdrawal symptoms without producing the euphoric “warm fuzzy” feeling typical of opioids. Researchers emphasize that 7‑OH carries genuine opioid hazards, including addiction, severe withdrawal, and respiratory depression that can lead to fatal overdose. In animal models, 7‑OH demonstrated the same respiratory‑depression risk as classic opioids, whereas kratom’s primary alkaloid did not. Prozialeck and colleagues explain that kratom’s pharmacology is more nuanced: it partially activates opioid receptors while also engaging adrenergic and serotonin pathways, resembling a hybrid of a weak opioid and an SNRI‑type antidepressant. This multimodal action likely accounts for its lower euphoric potential and the reported boost in energy among users. Nevertheless, experts caution that kratom is not without risk. Fatal poisonings often involve co‑ingestion of potent opioids such as fentanyl, suggesting that some users may cycle between kratom and stronger substances, raising overdose danger due to reduced opioid tolerance. Additionally, heavy‑metal contamination has been detected in certain kratom batches, though the source—soil, processing, or storage—remains unclear. Given these complexities, the consensus among scholars like Austin Zamarripa (Johns Hopkins) is that natural kratom should remain accessible, while concentrated 7‑OH products merit stricter regulation. “These products may offer meaningful benefits to some individuals, and those benefits could be lost if access is restricted too broadly,” Zamarripa said, urging a differentiated policy approach. As the debate unfolds, patients like Steven worry that a sweeping ban would ignore the nuanced safety profile of the plant. “There’s corn on the cob, there’s high‑fructose corn syrup, there’s whiskey— all derived from corn but fundamentally different,” he remarked, highlighting the need for targeted, evidence‑based regulation rather than a one‑size‑fits‑all prohibition.

A customer who invested in solar panels through Ikea's website is now £3,000 out of pocket after the collapse of the European operation of Soly, the installer's partner. The customer had signed up for the solar panels late last year, confident in the partnership with a well-known company like Ikea. Ikea had partnered with Soly to offer solar panels to customers, advertising the service on its website and promising 'Ikea pricing'. However, in February, the customer emailed Soly to check on the installation status and received an out-of-office notification. Subsequent emails bounced back, and phone numbers were no longer working. The customer discovered that Soly's European operation had gone bust, but Ikea's website still advertised the partnership, and agents assured them that Soly's UK division was still operational. However, the UK arm had entered liquidation in January, and Ikea quietly removed Soly from its website without informing customers who had paid deposits. The customer has contacted Ikea multiple times for help but received no reply. Ikea's silence has been criticized given the fanfare with which it launched its solar partnership last September. Customers were encouraged to invest in a 'better future life at home' in 'five easy steps' by applying for a free quote via the Ikea website. Soly's administrators, S&W; Group, have advised customers to register a claim, but the chance of a refund is uncertain. Unfortunately, the customer paid the deposit by bank transfer, making it unlikely that they will see their money again.